## REMARKS/ARGUMENTS

Upon entry of this amendment, claims 1-13 and 16 will be pending in the application.

Applicants have amended the specification to cross-reference the related applications and to

correct typographical errors. The claims have been amended to recite nucleic acid molecules

encoding a protein of SEQ ID NO:10 and related nucleic acid molecules, and the

polypeptides encoded thereby. No new matter has been introduced by way of this

amendment.

Applicants believe all claims now pending in this application are in condition for

allowance. The issuance of a Notice of Allowance at an early date is respectfully requested

If the Examiner believes a telephone conference would expedite prosecution of this

application, the undersigned may be contacted at 215-557-5908.

Respectfully submitted,

Date: July 23, 2003

Felicity E. Groth
Registration No. 47,042

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

20.   The method of claim 19, wherein the intracellular second messenger is selected from a group consisting of cAMP, calcium, and a reporter gene product.

21.   A compound identified using the method of Claim 17, wherein said compound is a modulator of a mammalian histamine H4 receptor.

22.   A compound identified using the method of Claim 17, wherein said compound is an agonist, antagonist, or inverse agonist of a mammalian histamine H4 receptor.

23.   A compound identified using the method of Claim 17, wherein said compound modulates the expression of the mammalian histamine H4 receptor protein.

24.   A pharmaceutical composition comprising a compound active in the method of Claim 17 and a pharmaceutically acceptable carrier.

25.   A method of treating a patient in need of such treatment for a condition that is mediated by a histamine H4 receptor comprising administration of a pharmaceutical composition of claim 24.

ORT1377